Sage Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SAGE research report →
About the company
Sage Therapeutics, Inc. functions as a biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of therapeutic agents aimed at central nervous system (CNS) conditions. Its primary medication is ZULRESSO, an intravenous form of brexanolone, prescribed for the treatment of postpartum depression (PPD) in adult patients.
- CEO
- Barry E. Greene
- IPO
- 2014
- Employees
- 353
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $544.94M
- P/E
- -4.82
- P/S
- 11.92
- P/B
- 1.47
- EV/EBITDA
- -4.02
- Div Yield
- 0.00%
- Gross Margin
- 98.69%
- Op Margin
- -265.56%
- Net Margin
- -244.66%
- ROE
- -28.74%
- ROIC
- -31.78%
- Revenue
- $41.24M · -52.30%
- Net Income
- $-400,666,000 · 26.01%
- EPS
- $-6.59 · 27.18%
- Op Income
- $-432,370,000
- FCF YoY
- 50.62%
- 52W High
- $9.36
- 52W Low
- $4.62
- 50D MA
- $8.29
- 200D MA
- $7.13
- Beta
- 0.30
- Avg Volume
- 2.48M
Get TickerSpark's AI analysis on SAGE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 25 | Quirk Michael C. | sell | 7,962 |
| Jul 31, 25 | Quirk Michael C. | sell | 36,000 |
| Jul 31, 25 | Quirk Michael C. | sell | 4,000 |
| Jul 31, 25 | Quirk Michael C. | sell | 24,999 |
| Jul 31, 25 | Federer Jessica | sell | 21,500 |
| Jul 31, 25 | Benecchi Christopher | sell | 12,500 |
| Jul 31, 25 | Benecchi Christopher | sell | 40,000 |
| Jul 31, 25 | Benecchi Christopher | sell | 28,053 |
| Jul 31, 25 | Benecchi Christopher | sell | 36,375 |
| Jul 31, 25 | COLA MICHAEL F | sell | 21,500 |
Our SAGE coverage
Recent articles, reports, and earnings notes.
No research on SAGE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SAGE report →Similar companies
Peers in the same neighborhood.